EMA Authorised: Rezurock (belumosudil mesilate) — Sanofi Winthrop Industrie

View source ↗

Summary

The European Medicines Agency authorised Rezurock (belumosudil mesilate) for graft-versus-host disease under conditional approval and orphan designation for San…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• REZUROCK (belumosudil)

Snippet

Status: Authorised. Therapeutic area: Graft vs Host Disease. MAH: Sanofi Winthrop Industrie. Decision date: 24/03/2026. Conditional approval. Orphan medicine